View the following video segments to learn more about the current thinking on Blepharitis. Our panel experts will present the latest data, challenges with historical treatment options, and the reason why proactive treatment of this disease can improve your surgical outcomes.
Download an Adobe PDF of the slides presented in this series.
- It is estimated that 182 million people have had at least one symptom of Blepharitis in the past year
- Dryness and irritation are the most commonly reported symptoms
- 34 million people experienced at least one of the three symptoms most commonly associated with blepharitis for least half the time of the past year
- 16% of patients that were incidentally diagnosed with blepharitis as part of a pre-surgical evaluation were asymptomatic
1. Introduction: Blepharitis Roundtable
2. Blepharitis in the US, 2009: A Perspective on Prevalence
3. Evolution of surgery and perioperative strategies
4. Impact on Patient Health and Surgical Results
5. The Importance of Treating Blepharitis in the Pre-operative Patient
6. Blepharitis Video Roundtable Take-Home Points
Ask the Expert
Dr. Bill Trattler answers your questions regarding the disease.
latest question
“How Azythromycin eye drops can be benefit for the managament of MGD?”
A number of studies have shown that using Azasite QHS for 2-4 weeks can lead to significant improvement of MGD. In my practice, I typically start treatment and evaluate patients 3 weeks later. Depending on the degree of improvement, I will either continue Azaite alone, or add topical cyclosporine or topical steroids to help with the condition.
In most cases, patients finish their treatment by 6 weeks, but occasionally I will have some patients with a more severe degree of MGD continue longer.
I hope this helpsDr. Bill Trattler
